Brolucizumab

Brolucizumab Uses, Dosage, Side Effects, Food Interaction and all others data.

Brolucizumab, also known as RTH258 or ESBA1008, is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

Brolucizumab was granted FDA approval in October 2019.

Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which reduces proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature. It has a long duration of action as it is given monthly. Patients should be counselled regarding the risk of endophthalmitis, retinal detachment, and arterial thromboembolic events following administration of this medication.

Trade Name Brolucizumab
Availability Prescription only
Generic Brolucizumab
Brolucizumab Other Names Brolucizumab, brolucizumab-dbll
Related Drugs Avastin, Eylea, Lucentis, Beovu, dexamethasone ophthalmic, Vabysmo, fluocinolone ophthalmic, aflibercept ophthalmic, ranibizumab ophthalmic
Weight dbll6mg/0.05ml
Type Intravitreal solution
Weight 26000.0 Da (approximate)
Protein binding

Monoclonal antibodies are generally not protein bound in serum.

Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Brolucizumab
Brolucizumab

Uses

Brolucizumab is an anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.

Brolucizumab is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

Brolucizumab is also used to associated treatment for these conditions: Neovascular Age Related Macular Degeneration

How Brolucizumab works

Brolucizumab is a vascular endothelial growth factor (VEGF) inhibitor which targets the major VEGF-A isoforms: VEGF110, VEGF121, and VEGF165. Inhibition of these VEGF-A isoforms reduce proliferation of endothelial cells, vascularization of the tissue, and permeability of the vasculature.

Toxicity

Data regarding the toxicity of brolucizumab is not readily available.

Food Interaction

No interactions found.

Volume of Distribution

Data regarding the volume of distribution is not readily available.

Elimination Route

A 3mg dose of brolucizumab reaches a Cmax of 20.7ng/mL with a Tmax of 20.3h and an AUC of 2480ng*h/mL. A 6mg dose of brolucizumab reaches a Cmax of 77.6ng/mL with a Tmax of 17.4h and an AUC of 9169ng*h/mL.

Half Life

The systemic half life of bolucizumab is 4.4±2.0 days. The elimination half life is 108h for a 3mg dose and 103h for a 6mg dose.

Clearance

Data regarding the clearance of brolucizumab is not readily available.

Elimination Route

Data regarding the route of elimination is not readily available. Monoclonal antibodies are generally not eliminated in the urine, and only a small amount is excreted in bile.

Innovators Monograph

You find simplified version here Brolucizumab

*** Taking medicines without doctor's advice can cause long-term problems.
Share